Cargando…
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
BACKGROUND: Myxoid liposarcoma is a histological subtype of liposarcoma particularly sensitive to trabectedin. In clinical use this drug does not cause cumulative toxicity, allowing prolonged treatment, generally until disease progression. No other effective therapies are available for trabectedin-r...
Autores principales: | Bello, Ezia, Brich, Silvia, Craparotta, Ilaria, Mannarino, Laura, Ballabio, Sara, Gatta, Raffaella, Marchini, Sergio, Carrassa, Laura, Matteo, Cristina, Sanfilippo, Roberta, Gronchi, Alessandro, Casali, Paolo Giovanni, Pilotti, Silvana, D’Incalci, Maurizio, Frapolli, Roberta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738121/ https://www.ncbi.nlm.nih.gov/pubmed/31409911 http://dx.doi.org/10.1038/s41416-019-0550-2 |
Ejemplares similares
-
Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2020) -
Identification of a gene expression driven progression pathway in myxoid liposarcoma
por: De Cecco, Loris, et al.
Publicado: (2014) -
A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma
por: Uboldi, Sarah, et al.
Publicado: (2012) -
Mechanism of action of trabectedin in desmoplastic small round cell tumor cells
por: Uboldi, S., et al.
Publicado: (2017) -
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)